Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz3. fázis

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

A legfontosabb adatok

Ki végzi
Neurocrine Biosciences
Hol
Ann Arbor, Atlanta, Aurora, Birmingham, Boston, Dallas, Hartford, Indianapolis, Los Angeles, Minneapolis, New Hyde Park, New York, Oklahoma City, Orange, Philadelphia, Pittsburgh, San Diego, San Francisco, Seattle, St Louis, Tulsa és Washington D.C. (Egyesült Államok)Mind a 22 helyszín megnézéseMég 9 másik országban, 18 helyszínen
Állapot
Fut, nem toboroz
Fázis
3. fázis
Résztvevők
103 fő vett részt
Kezdés
2021. jún. 25.
Várható befejezés
2027. aug.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Crinecerfont
  • Placebo
A regiszteradat frissítve
2025. február 5.

Ki vehet részt

Életkor
2 év – 17 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Be willing and able to adhere to the study procedures, including all requirements at the study center, and return for the follow-up visit
  • Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency
  • Be on a stable steroid regimen
  • Have elevated androgen levels
  • Participants of childbearing potential must be abstinent or agree to use appropriate birth control during the study

Ki nem vehet részt

  • Have received an investigational drug within 30 days before initial screening or plan to use an investigational drug (other than the study drug) during the study
  • Have current substance dependence or substance (drug) or alcohol abuse
  • Have had a significant blood loss or donated blood or blood products within 8 weeks prior to the study
  • Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy
  • Have a clinically significant unstable medical condition or chronic disease other than CAH
  • Have a history of cancer unless considered to be cured
  • Have a known history of clinically significant arrhythmia or abnormalities on electrocardiogram (ECG)
  • Have a known hypersensitivity to any corticotropin-releasing hormone antagonist
  • Have a diagnosis of any of the other forms of classic CAH

Helyszínek itt: Egyesült Államok

Még 9 másik országban, 18 helyszínen

  • Ann Arbor, MichiganHospital not named in the registry
  • Atlanta, GeorgiaHospital not named in the registry
  • Aurora, ColoradoHospital not named in the registry
  • Birmingham, AlabamaHospital not named in the registry
  • Boston, MassachusettsHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • Hartford, ConnecticutHospital not named in the registry
  • Indianapolis, IndianaHospital not named in the registry
  • Los Angeles, CaliforniaHospital not named in the registry
  • Minneapolis, MinnesotaHospital not named in the registry
  • New Hyde Park, New YorkHospital not named in the registry
  • New YorkHospital not named in the registry
  • Oklahoma City, OklahomaHospital not named in the registry
  • Orange, CaliforniaHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • Pittsburgh, PennsylvaniaHospital not named in the registry
  • San Diego, CaliforniaHospital not named in the registry
  • San Francisco, CaliforniaHospital not named in the registry
  • Seattle, WashingtonHospital not named in the registry
  • St Louis, MissouriHospital not named in the registry
  • Tulsa, OklahomaHospital not named in the registry
  • Washington D.C., District of ColumbiaHospital not named in the registry

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 28 weeks in approximately 81 pediatric participants with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of a 28-week double blind, placebo-controlled period, followed by 24 weeks of open-label treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 14 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).

A vizsgálat 2 csoportja

  • CrinecerfontA vizsgált kezelés

    Crinecerfont solution or capsule, administered orally, twice daily for 28 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 24 weeks.

  • PlaceboPlacebo, összehasonlításként

    Placebo solution or capsule, administered orally, twice daily for 28 weeks, followed by active treatment with crinecerfont for at least 24 weeks.

    Kezelés: Crinecerfont és Placebo

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Publikációk
A regiszteradat frissítve
2025. február 5.